TWI225790B - New vaccine and method of use - Google Patents
New vaccine and method of use Download PDFInfo
- Publication number
- TWI225790B TWI225790B TW88115828A TW88115828A TWI225790B TW I225790 B TWI225790 B TW I225790B TW 88115828 A TW88115828 A TW 88115828A TW 88115828 A TW88115828 A TW 88115828A TW I225790 B TWI225790 B TW I225790B
- Authority
- TW
- Taiwan
- Prior art keywords
- vaccine
- vaccine formulation
- item
- scope
- patent application
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 142
- 238000000034 method Methods 0.000 title claims abstract description 25
- 239000000427 antigen Substances 0.000 claims abstract description 60
- 102000036639 antigens Human genes 0.000 claims abstract description 60
- 108091007433 antigens Proteins 0.000 claims abstract description 60
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 238000009472 formulation Methods 0.000 claims abstract description 29
- 239000002671 adjuvant Substances 0.000 claims abstract description 26
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims abstract description 7
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims abstract description 7
- 239000012634 fragment Substances 0.000 claims abstract description 6
- 230000001939 inductive effect Effects 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 64
- 208000001688 Herpes Genitalis Diseases 0.000 claims description 63
- 201000004946 genital herpes Diseases 0.000 claims description 63
- 239000012528 membrane Substances 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 241000606161 Chlamydia Species 0.000 claims description 8
- 241000606790 Haemophilus Species 0.000 claims description 7
- 208000006379 syphilis Diseases 0.000 claims description 7
- 241000589884 Treponema pallidum Species 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 239000007764 o/w emulsion Substances 0.000 claims description 3
- 241000606834 [Haemophilus] ducreyi Species 0.000 claims description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000003796 chancre Diseases 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 101900228213 Human herpesvirus 2 Envelope glycoprotein D Proteins 0.000 claims 2
- 241000588653 Neisseria Species 0.000 claims 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims 1
- 229910021536 Zeolite Inorganic materials 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical group O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims 1
- 239000010457 zeolite Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 45
- 230000002265 prevention Effects 0.000 abstract description 27
- 238000011282 treatment Methods 0.000 abstract description 23
- 208000019802 Sexually transmitted disease Diseases 0.000 abstract description 14
- 244000052769 pathogen Species 0.000 abstract description 8
- 230000001900 immune effect Effects 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 description 33
- 229940068196 placebo Drugs 0.000 description 31
- 239000000902 placebo Substances 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 30
- 201000010099 disease Diseases 0.000 description 29
- 102000004169 proteins and genes Human genes 0.000 description 26
- 238000002255 vaccination Methods 0.000 description 25
- 241000606153 Chlamydia trachomatis Species 0.000 description 21
- 229940038705 chlamydia trachomatis Drugs 0.000 description 20
- 230000007774 longterm Effects 0.000 description 18
- 230000001681 protective effect Effects 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 208000009889 Herpes Simplex Diseases 0.000 description 15
- 101710164702 Major outer membrane protein Proteins 0.000 description 13
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000004392 genitalia Anatomy 0.000 description 10
- 241000498849 Chlamydiales Species 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000001568 sexual effect Effects 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 206010048461 Genital infection Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 101710116435 Outer membrane protein Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- -1 iL_5 Proteins 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 5
- 208000035415 Reinfection Diseases 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000000509 infertility Diseases 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010008263 Cervical dysplasia Diseases 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000341655 Human papillomavirus type 16 Species 0.000 description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 101710188053 Protein D Proteins 0.000 description 4
- 101710132893 Resolvase Proteins 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 229940037003 alum Drugs 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000001325 log-rank test Methods 0.000 description 4
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- 208000007190 Chlamydia Infections Diseases 0.000 description 3
- 108700042132 Chlamydia trachomatis omp1 Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 208000007893 Salpingitis Diseases 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- 108010031133 Transferrin-Binding Protein A Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 229940001442 combination vaccine Drugs 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002480 immunoprotective effect Effects 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229920000056 polyoxyethylene ether Polymers 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000005000 reproductive tract Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 206010044325 trachoma Diseases 0.000 description 3
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000022555 Genital disease Diseases 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 108010031127 Transferrin-Binding Protein B Proteins 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- JIWAALDUIFCBLV-UHFFFAOYSA-N oxoosmium Chemical compound [Os]=O JIWAALDUIFCBLV-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 101100152731 Arabidopsis thaliana TH2 gene Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241001185363 Chlamydiae Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000388186 Deltapapillomavirus 4 Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 206010053028 Gynaecological chlamydia infection Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 101710127774 Stress response protein Proteins 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001358 anti-chlamydial effect Effects 0.000 description 1
- 230000003622 anti-hsv Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 108010003871 heme receptor Proteins 0.000 description 1
- 229940124725 herpes simplex vaccine Drugs 0.000 description 1
- 101150071752 hgbA gene Proteins 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 108700027921 interferon tau Proteins 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229910000487 osmium oxide Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 102000007739 porin activity proteins Human genes 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000021127 protein binding proteins Human genes 0.000 description 1
- 108091011138 protein binding proteins Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9819898A GB9819898D0 (en) | 1998-09-11 | 1998-09-11 | New vaccine and method of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI225790B true TWI225790B (en) | 2005-01-01 |
Family
ID=10838766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW88115828A TWI225790B (en) | 1998-09-11 | 1999-09-14 | New vaccine and method of use |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1109574B1 (https=) |
| JP (1) | JP2002524532A (https=) |
| KR (1) | KR100777896B1 (https=) |
| CN (2) | CN1325311A (https=) |
| AR (1) | AR021798A1 (https=) |
| AT (1) | ATE392214T1 (https=) |
| AU (1) | AU744989B2 (https=) |
| BR (1) | BR9913630A (https=) |
| CA (1) | CA2343399C (https=) |
| CO (1) | CO5090882A1 (https=) |
| CY (1) | CY1108147T1 (https=) |
| CZ (1) | CZ302808B6 (https=) |
| DE (1) | DE69938555T2 (https=) |
| DK (1) | DK1109574T3 (https=) |
| ES (1) | ES2304068T3 (https=) |
| GB (1) | GB9819898D0 (https=) |
| HU (1) | HUP0104297A3 (https=) |
| IL (1) | IL141843A0 (https=) |
| MY (1) | MY122216A (https=) |
| NO (1) | NO329522B1 (https=) |
| NZ (1) | NZ510425A (https=) |
| PL (1) | PL199545B1 (https=) |
| PT (1) | PT1109574E (https=) |
| SI (1) | SI1109574T1 (https=) |
| TR (1) | TR200100948T2 (https=) |
| TW (1) | TWI225790B (https=) |
| WO (1) | WO2000015255A1 (https=) |
| ZA (1) | ZA200101987B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69935606T9 (de) | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | Adjuvanzsysteme und impfstoffe |
| GB9921146D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
| CA2630220C (en) | 2005-11-22 | 2020-10-13 | Doris Coit | Norovirus and sapovirus antigens |
| US20090317421A1 (en) | 2006-01-18 | 2009-12-24 | Dominique Missiakas | Compositions and methods related to staphylococcal bacterium proteins |
| CA2699513C (en) | 2007-09-12 | 2018-03-13 | Novartis Ag | Gas57 mutant antigens and gas57 antibodies |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| WO2011008400A2 (en) | 2009-06-16 | 2011-01-20 | Novartis Ag | High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays |
| WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
| AU2011237393B2 (en) | 2010-04-08 | 2015-01-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | B-cell antigen presenting cell assay |
| KR20130121699A (ko) | 2010-05-28 | 2013-11-06 | 테트리스 온라인, 인코포레이티드 | 상호작용 혼성 비동기 컴퓨터 게임 기반구조 |
| CA2843854A1 (en) | 2011-07-01 | 2013-01-10 | The Regents Of The University Of California | Herpes virus vaccine and methods of use |
| US11071745B2 (en) | 2014-07-07 | 2021-07-27 | Elian Llc | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits |
| JP7525976B2 (ja) * | 2014-07-07 | 2024-07-31 | エリアン リミテッド ライアビリティ カンパニー | ウイルス予防治療方法及び曝露前予防キット |
| BR112018017141A2 (pt) | 2016-02-22 | 2019-01-02 | Boehringer Ingelheim Vetmedica Gmbh | método para a imobilização de biomoléculas |
| WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105992D0 (en) * | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
| ATE157882T1 (de) * | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| GB9506863D0 (en) * | 1995-04-03 | 1995-05-24 | Smithkline Beecham Biolog | Vaccines |
-
1998
- 1998-09-11 GB GB9819898A patent/GB9819898D0/en not_active Ceased
-
1999
- 1999-09-08 CN CN99813127A patent/CN1325311A/zh active Pending
- 1999-09-08 SI SI9931008T patent/SI1109574T1/sl unknown
- 1999-09-08 HU HU0104297A patent/HUP0104297A3/hu unknown
- 1999-09-08 CN CNA2007101469740A patent/CN101130070A/zh active Pending
- 1999-09-08 ES ES99969034T patent/ES2304068T3/es not_active Expired - Lifetime
- 1999-09-08 CZ CZ20010887A patent/CZ302808B6/cs not_active IP Right Cessation
- 1999-09-08 JP JP2000569839A patent/JP2002524532A/ja active Pending
- 1999-09-08 AU AU59752/99A patent/AU744989B2/en not_active Ceased
- 1999-09-08 KR KR1020017003161A patent/KR100777896B1/ko not_active Expired - Fee Related
- 1999-09-08 PL PL346651A patent/PL199545B1/pl not_active IP Right Cessation
- 1999-09-08 AT AT99969034T patent/ATE392214T1/de active
- 1999-09-08 BR BR9913630A patent/BR9913630A/pt not_active Application Discontinuation
- 1999-09-08 EP EP99969034A patent/EP1109574B1/en not_active Expired - Lifetime
- 1999-09-08 CA CA 2343399 patent/CA2343399C/en not_active Expired - Fee Related
- 1999-09-08 NZ NZ51042599A patent/NZ510425A/xx not_active IP Right Cessation
- 1999-09-08 PT PT99969034T patent/PT1109574E/pt unknown
- 1999-09-08 IL IL14184399A patent/IL141843A0/xx not_active IP Right Cessation
- 1999-09-08 WO PCT/EP1999/006623 patent/WO2000015255A1/en not_active Ceased
- 1999-09-08 DE DE1999638555 patent/DE69938555T2/de not_active Expired - Lifetime
- 1999-09-08 DK DK99969034T patent/DK1109574T3/da active
- 1999-09-08 TR TR200100948T patent/TR200100948T2/xx unknown
- 1999-09-09 AR ARP990104534 patent/AR021798A1/es unknown
- 1999-09-09 MY MYPI99003916A patent/MY122216A/en unknown
- 1999-09-10 CO CO99057608A patent/CO5090882A1/es unknown
- 1999-09-14 TW TW88115828A patent/TWI225790B/zh not_active IP Right Cessation
-
2001
- 2001-03-08 NO NO20011193A patent/NO329522B1/no not_active IP Right Cessation
- 2001-03-09 ZA ZA200101987A patent/ZA200101987B/en unknown
-
2008
- 2008-06-18 CY CY081100643T patent/CY1108147T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6692752B1 (en) | Methods of treating human females susceptible to HSV infection | |
| TWI225790B (en) | New vaccine and method of use | |
| JP7506930B2 (ja) | クラミジア種（Ｃｈｌａｍｙｄｉａ ｓｐ．）に対するワクチン | |
| ES2732815T3 (es) | Vacunas frente al virus del herpes simple de tipo 2: composiciones y métodos para provocar una respuesta inmunitaria | |
| US7892567B2 (en) | Methods and compositions for immunization against chlamydial infection and disease | |
| CN103998056B (zh) | 用于接种抗金黄色葡萄球菌疫苗的方法和组合物 | |
| US9974849B2 (en) | Human Papilloma virus therapeutic vaccine | |
| CN103501808A (zh) | 用于针对肺炎链球菌免疫的组合物 | |
| JP2015519305A (ja) | ヒストフィルス・ソムニの外膜タンパク質とその方法 | |
| US9926342B2 (en) | Recombinant VapA and VapC peptides and uses thereof | |
| CA2275896A1 (en) | Chlamydia vaccines | |
| JPWO2018064232A5 (https=) | ||
| US20180043008A1 (en) | Recall antigen for promoting t-helper type 1 response | |
| MXPA01002532A (en) | Vaccine against sexually transmitted diseases | |
| AU2932502A (en) | Vaccine against sexually transmitted diseases | |
| US20180028627A1 (en) | Treatment vaccine for prostate cancer | |
| EP4032545A1 (en) | Immunogenic composition and vaccine containing chlamydia ssp. surface antigens and its use | |
| HK1037978B (en) | Vaccine against sexually transmitted diseases | |
| Pan et al. | Modulation of desmoglein-3-specific T cell response and pathogenic antibody generation in mice | |
| Farris | Mechanisms of major outer membrane protein (MOMP)-vaccine induced protective immunity against Chlamydia muridarum genital infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |